Phathom Pharmaceuticals (PHAT) Financials

$4.69 -0.01 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$4.72 +0.03 (+0.64%)

As of 05:36 PM Eastern

Annual Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-334	-202	-198
Consolidated Net Income / (Loss)	-334	-202	-198
Net Income / (Loss) Continuing Operations	-334	-202	-198
Total Pre-Tax Income	-334	-202	-198
Total Operating Income	-277	-167	-172
Total Gross Profit	47	0.52	0.00
Total Revenue	55	0.68	0.00
Operating Revenue	55	0.68	0.00
Total Cost of Revenue	7.97	0.17	0.00
Operating Cost of Revenue	7.97	0.17	0.00
Total Operating Expenses	325	168	172
Selling, General & Admin Expense	291	118	101
Research & Development Expense	34	50	71
Total Other Income / (Expense), net	-57	-34	-25
Interest Expense	72	42	27
Interest & Investment Income	15	7.88	2.13
Other Income / (Expense), net	-0.01	-0.19	-0.11
Basic Earnings per Share	($5.29)	($3.93)	($5.05)
Weighted Average Basic Shares Outstanding	63.18M	51.29M	39.12M
Diluted Earnings per Share	($5.29)	($3.93)	($5.05)
Weighted Average Diluted Shares Outstanding	63.18M	51.29M	39.12M
Weighted Average Basic & Diluted Shares Outstanding	69.64M	58.48M	41.97M

This table shows Phathom Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-74	-86	-91	-83	-80	-43	-41	-38	-55	-51
Consolidated Net Income / (Loss)	-74	-86	-91	-83	-80	-43	-41	-38	-55	-51
Net Income / (Loss) Continuing Operations	-74	-86	-91	-83	-80	-43	-41	-38	-55	-51
Total Pre-Tax Income	-74	-86	-91	-83	-80	-43	-41	-38	-55	-51
Total Operating Income	-59	-71	-77	-70	-70	-36	-32	-30	-47	-43
Total Gross Profit	26	14	5.95	1.49	0.52	0.00	0.00	0.00	-	0.00
Total Revenue	30	16	7.32	1.91	0.68	0.00	0.00	0.00	-	0.00
Operating Revenue	30	16	7.32	1.91	0.68	0.00	0.00	0.00	-	-
Total Cost of Revenue	3.82	2.36	1.38	0.43	0.17	0.00	0.00	0.00	-	0.00
Operating Cost of Revenue	3.82	2.36	1.38	0.43	0.17	0.00	0.00	0.00	-	-
Total Operating Expenses	85	85	83	71	70	36	32	30	47	43
Selling, General & Admin Expense	77	76	76	62	57	23	19	19	31	24
Research & Development Expense	8.58	8.69	7.38	9.43	13	12	13	11	16	19
Total Other Income / (Expense), net	-15	-15	-14	-13	-9.70	-7.58	-9.26	-7.74	-8.41	-8.56
Interest Expense	19	18	18	17	13	10	9.62	9.22	9.60	9.28
Interest & Investment Income	3.51	3.71	3.62	4.31	3.35	2.72	0.35	1.46	1.29	0.73
Other Income / (Expense), net	0.05	-0.01	-0.01	-0.04	-0.01	-0.20	0.00	0.02	-0.09	-0.01
Basic Earnings per Share	($0.99)	($1.32)	($1.56)	($1.42)	($1.44)	($0.76)	($0.84)	($0.89)	($1.33)	($1.32)
Weighted Average Basic Shares Outstanding	63.18M	64.63M	58.56M	58.37M	51.29M	56.78M	48.50M	42.35M	39.12M	38.82M
Diluted Earnings per Share	($0.99)	($1.32)	($1.56)	($1.42)	($1.44)	($0.76)	($0.84)	($0.89)	($1.33)	($1.32)
Weighted Average Diluted Shares Outstanding	63.18M	64.63M	58.56M	58.37M	51.29M	56.78M	48.50M	42.35M	39.12M	38.82M
Weighted Average Basic & Diluted Shares Outstanding	69.64M	68.38M	59.59M	58.54M	58.48M	57.25M	56.80M	43.61M	41.97M	41.62M

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-84	228	-28
Net Cash From Operating Activities	-267	-138	-147
Net Cash From Continuing Operating Activities	-267	-138	-147
Net Income / (Loss) Continuing Operations	-334	-202	-198
Consolidated Net Income / (Loss)	-334	-202	-198
Depreciation Expense	0.80	0.58	0.62
Amortization Expense	2.19	1.88	2.11
Non-Cash Adjustments To Reconcile Net Income	80	75	41
Changes in Operating Assets and Liabilities, net	-15	-14	7.08
Net Cash From Investing Activities	-0.14	-1.63	-1.04
Net Cash From Continuing Investing Activities	-0.14	-1.63	-1.04
Purchase of Property, Plant & Equipment	-0.14	-1.63	-1.04
Net Cash From Financing Activities	183	368	120
Net Cash From Continuing Financing Activities	183	368	120
Issuance of Debt	181	181	0.00
Issuance of Common Equity	0.00	14	25
Other Financing Activities, net	1.60	173	95
Cash Interest Paid	17	11	7.03

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-37	58	-46	-59	168	-33	119	-26	-41	-11
Net Cash From Operating Activities	-63	-64	-71	-69	-44	-32	-22	-40	-41	-35
Net Cash From Continuing Operating Activities	-63	-64	-71	-69	-44	-32	-22	-40	-41	-35
Net Income / (Loss) Continuing Operations	-74	-86	-91	-83	-80	-43	-41	-38	-55	-51
Consolidated Net Income / (Loss)	-74	-86	-91	-83	-80	-43	-41	-38	-55	-51
Depreciation Expense	0.19	0.19	0.20	0.21	0.19	0.12	0.12	0.15	0.17	0.18
Amortization Expense	0.63	0.59	0.50	0.47	0.57	0.54	0.27	0.50	0.50	0.56
Non-Cash Adjustments To Reconcile Net Income	19	20	21	20	34	14	14	14	13	12
Changes in Operating Assets and Liabilities, net	-9.08	1.34	-0.67	-7.07	1.29	-3.12	4.38	-16	-0.07	2.91
Net Cash From Investing Activities	-0.01	-0.04	-0.05	-0.04	-0.48	-0.94	-0.01	-0.21	-0.41	-0.13
Net Cash From Continuing Investing Activities	-0.01	-0.04	-0.05	-0.04	-0.48	-0.94	-0.01	-0.21	-0.41	-0.13
Purchase of Property, Plant & Equipment	-0.01	-0.04	-0.05	-0.04	-0.48	-0.94	-0.01	-0.21	-0.41	-0.13
Net Cash From Financing Activities	26	122	25	9.90	212	0.01	142	14	-	25
Net Cash From Continuing Financing Activities	26	122	25	9.90	212	0.01	142	14	-	25
Issuance of Debt	25	122	25	9.90	39	-	141	0.00	-	-
Other Financing Activities, net	1.30	0.28	-	-	173	0.01	-	-	-	-
Cash Interest Paid	4.82	4.66	4.08	3.74	2.91	2.91	2.76	2.55	2.10	2.02

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	378	414	165
Total Current Assets	360	397	161
Cash & Equivalents	297	381	155
Restricted Cash	2.86	2.86	0.51
Accounts Receivable	39	1.64	0.00
Inventories, net	3.21	1.21	0.00
Prepaid Expenses	21	13	5.13
Plant, Property, & Equipment, net	1.48	2.15	1.21
Total Noncurrent Assets	14	11	2.59
Other Noncurrent Operating Assets	14	11	2.59
Total Liabilities & Shareholders' Equity	378	414	165
Total Liabilities	632	487	240
Total Current Liabilities	86	39	26
Accounts Payable	11	13	10.00
Accrued Expenses	53	17	15
Current Deferred Revenue	20	7.11	0.00
Other Current Liabilities	0.50	0.73	0.71
Other Current Nonoperating Liabilities	1.71	1.15	0.85
Total Noncurrent Liabilities	546	448	213
Long-Term Debt	201	138	95
Noncurrent Deferred Revenue	333	300	110
Other Noncurrent Operating Liabilities	12	10	8.60
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-254	-73	-75
Total Preferred & Common Equity	-254	-73	-75
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-254	-73	-75
Common Stock	1,009	856	652
Retained Earnings	-1,263	-929	-727
Treasury Stock	0.00	0.00	0.00

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	387	319	356	237	265	144	202
Total Current Assets	374	305	340	227	258	140	198
Cash & Equivalents	335	276	322	214	249	130	197
Restricted Cash	2.86	2.86	2.87	-	-	-	-
Accounts Receivable	21	11	3.88	-	-	-	-
Inventories, net	3.11	2.18	1.46	0.11	0.11	-	-
Prepaid Expenses	15	15	13	13	8.76	10	0.98
Plant, Property, & Equipment, net	1.66	1.81	1.96	1.98	1.16	1.28	0.83
Total Noncurrent Assets	8.71	9.91	11	8.29	6.16	2.89	3.29
Other Noncurrent Operating Assets	8.71	9.91	11	8.29	6.16	2.89	3.29
Total Liabilities & Shareholders' Equity	387	319	356	237	265	144	202
Total Liabilities	574	553	505	255	247	234	228
Total Current Liabilities	65	47	43	24	22	14	23
Accounts Payable	7.13	7.66	8.40	5.79	4.17	4.81	7.14
Accrued Expenses	36	27	17	14	15	8.02	13
Current Deferred Revenue	20	9.91	16	2.39	0.28	-	-
Other Current Liabilities	0.68	0.72	0.73	0.72	0.72	0.71	1.63
Other Current Nonoperating Liabilities	1.52	1.43	1.31	0.96	0.93	0.91	0.69
Total Noncurrent Liabilities	509	506	462	231	226	220	205
Long-Term Debt	176	174	149	99	98	97	94
Noncurrent Deferred Revenue	322	321	303	123	120	-	-
Other Noncurrent Operating Liabilities	11	11	9.99	8.13	8.29	123	112
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-187	-234	-149	-18	18	-90	-26
Total Preferred & Common Equity	-187	-234	-149	-18	18	-90	-26
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-187	-234	-149	-18	18	-90	-26
Common Stock	1,001	869	863	831	823	675	646
Retained Earnings	-1,189	-1,103	-1,012	-849	-806	-765	-672
Treasury Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	8,001.47%	0.00%	0.00%
EBITDA Growth	-66.31%	2.81%	-27.67%
EBIT Growth	-65.66%	2.93%	-25.82%
NOPAT Growth	-65.84%	2.97%	-27.66%
Net Income Growth	-65.84%	-1.96%	-37.42%
EPS Growth	-34.61%	22.18%	-29.82%
Operating Cash Flow Growth	-93.90%	6.11%	1.30%
Free Cash Flow Firm Growth	-343.76%	1,037.16%	94.08%
Invested Capital Growth	-10.24%	-136.30%	-542.26%
Revenue Q/Q Growth	110.32%	0.00%	0.00%
EBITDA Q/Q Growth	3.72%	-16.25%	-8.74%
EBIT Q/Q Growth	3.65%	-16.04%	-8.61%
NOPAT Q/Q Growth	3.63%	-16.13%	-8.56%
Net Income Q/Q Growth	1.51%	-13.85%	-10.77%
EPS Q/Q Growth	7.84%	-2.88%	-8.14%
Operating Cash Flow Q/Q Growth	-7.96%	-2.04%	0.15%
Free Cash Flow Firm Q/Q Growth	-1,205.84%	167.46%	53.16%
Invested Capital Q/Q Growth	-0.92%	-142.34%	-4.58%
Profitability Metrics	-	-	-
Gross Margin	85.57%	75.51%	0.00%
EBITDA Margin	-496.79%	-24,200.59%	0.00%
Operating Margin	-502.18%	-24,532.55%	0.00%
EBIT Margin	-502.20%	-24,560.12%	0.00%
Profit (Net Income) Margin	-605.09%	-29,558.94%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	120.49%	120.35%	114.59%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	204.89%	273.21%	14,877.58%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-70.06%	-57.89%	0.00%
Return on Assets (ROA)	-84.41%	-69.68%	0.00%
Return on Common Equity (ROCE)	204.89%	273.21%	14,877.58%
Return on Equity Simple (ROE_SIMPLE)	131.84%	277.07%	264.29%
Net Operating Profit after Tax (NOPAT)	-194	-117	-121
NOPAT Margin	-351.53%	-17,172.79%	0.00%
Net Nonoperating Expense Percent (NNEP)	-81.86%	-55.39%	-100.75%
Return On Investment Capital (ROIC_SIMPLE)	372.29%	-179.95%	-
Cost of Revenue to Revenue	14.43%	24.49%	0.00%
SG&A Expenses to Revenue	526.07%	17,291.50%	0.00%
R&D to Revenue	61.68%	7,316.57%	0.00%
Operating Expenses to Revenue	587.75%	24,608.06%	0.00%
Earnings before Interest and Taxes (EBIT)	-277	-168	-173
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-274	-165	-170
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	10.05	766.45	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	8.26	405.13	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	4.17	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-0.79	-1.89	-1.27
Long-Term Debt to Equity	-0.79	-1.89	-1.27
Financial Leverage	1.05	2.07	57.52
Leverage Ratio	-2.43	-3.92	-133.27
Compound Leverage Factor	-2.92	-4.72	-152.72
Debt to Total Capital	-386.06%	211.79%	465.84%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-386.06%	211.79%	465.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	486.06%	-111.79%	-365.84%
Debt to EBITDA	-0.73	-0.84	-0.56
Net Debt to EBITDA	0.36	1.49	0.36
Long-Term Debt to EBITDA	-0.73	-0.84	-0.56
Debt to NOPAT	-1.04	-1.18	-0.79
Net Debt to NOPAT	0.51	2.10	0.50
Long-Term Debt to NOPAT	-1.04	-1.18	-0.79
Altman Z-Score	-5.55	-2.79	-7.48
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	4.20	10.25	6.12
Quick Ratio	3.92	9.88	5.92
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-162	66	-7.08
Operating Cash Flow to CapEx	-197,607.41%	-8,419.83%	-14,075.89%
Free Cash Flow to Firm to Interest Expense	-2.25	1.58	-0.26
Operating Cash Flow to Interest Expense	-3.70	-3.28	-5.37
Operating Cash Flow Less CapEx to Interest Expense	-3.71	-3.32	-5.40
Efficiency Ratios	-	-	-
Asset Turnover	0.14	0.00	0.00
Accounts Receivable Turnover	2.73	0.00	0.00
Inventory Turnover	3.61	0.00	0.00
Fixed Asset Turnover	30.51	0.41	0.00
Accounts Payable Turnover	0.69	0.01	0.00
Days Sales Outstanding (DSO)	133.56	0.00	0.00
Days Inventory Outstanding (DIO)	101.08	0.00	0.00
Days Payable Outstanding (DPO)	528.94	24,695.42	0.00
Cash Conversion Cycle (CCC)	-294.30	-24,695.42	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-351	-318	-135
Invested Capital Turnover	-0.17	0.00	0.00
Increase / (Decrease) in Invested Capital	-33	-183	-114
Enterprise Value (EV)	457	276	406
Market Capitalization	555	523	467
Book Value per Share	($3.71)	($1.27)	($1.80)
Tangible Book Value per Share	($3.71)	($1.27)	($1.80)
Total Capital	-52	65	20
Total Debt	201	138	95
Total Long-Term Debt	201	138	95
Net Debt	-99	-246	-61
Capital Expenditures (CapEx)	0.14	1.63	1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-26	-22
Debt-free Net Working Capital (DFNWC)	274	359	134
Net Working Capital (NWC)	274	359	134
Net Nonoperating Expense (NNE)	140	84	77
Net Nonoperating Obligations (NNO)	-97	-245	-60
Total Depreciation and Amortization (D&A)	2.99	2.45	2.73
Debt-free, Cash-free Net Working Capital to Revenue	-46.55%	-3,754.40%	0.00%
Debt-free Net Working Capital to Revenue	496.64%	52,588.12%	0.00%
Net Working Capital to Revenue	496.64%	52,588.12%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($5.29)	$0.00	($5.05)
Adjusted Weighted Average Basic Shares Outstanding	63.18M	0.00	39.12M
Adjusted Diluted Earnings per Share	($5.29)	$0.00	($5.05)
Adjusted Weighted Average Diluted Shares Outstanding	63.18M	0.00	39.12M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.64M	0.00	41.97M
Normalized Net Operating Profit after Tax (NOPAT)	-194	-117	-121
Normalized NOPAT Margin	-351.53%	-17,172.79%	0.00%
Pre Tax Income Margin	-605.09%	-29,558.94%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-3.85	-3.99	-6.32
NOPAT to Interest Expense	-2.70	-2.79	-4.42
EBIT Less CapEx to Interest Expense	-3.86	-4.03	-6.36
NOPAT Less CapEx to Interest Expense	-2.70	-2.83	-4.46
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4,249.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	15.32%	-98.97%	-144.74%	-135.62%	-50.08%	15.81%	29.95%	21.07%	-42.12%	-27.97%
EBIT Growth	15.05%	-97.47%	-143.88%	-132.88%	-49.55%	15.71%	30.13%	20.72%	-41.37%	-20.90%
NOPAT Growth	14.97%	-98.54%	-143.84%	-132.58%	-49.81%	16.15%	30.12%	20.65%	-41.17%	-28.34%
Net Income Growth	6.43%	-97.90%	-123.23%	-119.10%	-44.55%	15.36%	19.55%	7.01%	-53.65%	-39.36%
EPS Growth	31.25%	-73.68%	-85.71%	-59.55%	-8.27%	42.42%	36.84%	16.82%	-40.00%	-34.69%
Operating Cash Flow Growth	-44.89%	-99.20%	-218.56%	-73.99%	-6.72%	8.86%	13.67%	11.37%	0.54%	-20.47%
Free Cash Flow Firm Growth	-106.72%	842.99%	1,458.93%	64.18%	66.12%	-133.82%	-118.43%	310.67%	268.36%	586.46%
Invested Capital Growth	-10.24%	-164.72%	-154.37%	-164.50%	-136.30%	-1.97%	-9.16%	-1,331.65%	-542.26%	-294.56%
Revenue Q/Q Growth	81.41%	123.27%	283.05%	180.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	16.39%	8.60%	-10.53%	-0.25%	-96.45%	-12.43%	-6.42%	36.15%	-10.21%	6.45%
EBIT Q/Q Growth	16.15%	8.41%	-10.44%	-0.15%	-94.92%	-13.12%	-5.46%	35.68%	-9.85%	6.23%
NOPAT Q/Q Growth	16.07%	8.41%	-10.50%	-0.11%	-95.95%	-12.49%	-5.40%	35.52%	-9.67%	6.25%
Net Income Q/Q Growth	13.00%	6.42%	-10.37%	-4.12%	-84.01%	-5.56%	-8.33%	31.31%	-7.74%	-0.34%
EPS Q/Q Growth	25.00%	15.38%	-9.86%	1.39%	-89.47%	9.52%	5.62%	33.08%	-0.76%	0.75%
Operating Cash Flow Q/Q Growth	0.18%	10.11%	-2.46%	-57.59%	-37.23%	-43.76%	44.04%	3.34%	-17.21%	-36.16%
Free Cash Flow Firm Q/Q Growth	-105.42%	10.74%	-1.07%	13.05%	699.92%	-102.54%	-111.95%	14.38%	22.13%	10.35%
Invested Capital Q/Q Growth	-0.92%	-3.06%	-4.27%	-1.65%	-142.34%	0.97%	-8.42%	9.19%	-4.58%	-6.02%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.14%	85.59%	81.21%	77.72%	75.51%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-197.36%	-428.23%	-1,046.00%	-3,624.95%	-10,137.54%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-200.30%	-432.95%	-1,055.43%	-3,658.68%	-10,245.60%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-200.13%	-433.00%	-1,055.52%	-3,660.93%	-10,247.65%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-250.98%	-523.34%	-1,248.58%	-4,333.26%	-11,667.16%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	125.41%	120.86%	118.29%	118.37%	113.85%	120.60%	129.24%	125.81%	117.79%	120.10%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	204.89%	331.35%	274.81%	206.65%	273.21%	801.29%	-3,489.00%	747.21%	14,877.58%	-463.29%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-27.92%	-36.46%	-35.83%	-37.95%	-24.16%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-35.01%	-44.06%	-42.38%	-44.92%	-27.50%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	204.89%	331.35%	274.81%	206.65%	273.21%	801.29%	-3,489.00%	747.21%	14,877.58%	-463.29%
Return on Equity Simple (ROE_SIMPLE)	0.00%	181.41%	127.06%	166.08%	0.00%	996.28%	-1,050.66%	216.06%	0.00%	675.56%
Net Operating Profit after Tax (NOPAT)	-42	-50	-54	-49	-49	-25	-22	-21	-33	-30
NOPAT Margin	-140.21%	-303.07%	-738.80%	-2,561.08%	-7,171.92%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-19.20%	-26.32%	-29.47%	-32.77%	-20.10%	-16.95%	-14.20%	-42.65%	-29.30%	-17.89%
Return On Investment Capital (ROIC_SIMPLE)	79.72%	-	-	-	-75.15%	-	-	-	-	-
Cost of Revenue to Revenue	12.86%	14.41%	18.79%	22.28%	24.49%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	258.51%	465.38%	1,035.94%	3,243.20%	8,357.33%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	28.93%	53.16%	100.71%	493.20%	1,963.78%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	287.44%	518.54%	1,136.65%	3,736.40%	10,321.11%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-59	-71	-77	-70	-70	-36	-32	-30	-47	-43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-59	-70	-77	-69	-69	-35	-31	-29	-46	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	35.49	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	35.49	0.00	0.00	0.00
Price to Revenue (P/Rev)	10.05	41.01	60.73	239.41	766.45	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	8.26	34.86	50.18	171.53	405.13	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	62.63	18.02	7.94	4.17	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.79	-0.94	-0.75	-1.00	-1.89	-5.58	5.56	-1.07	-1.27	-3.55
Long-Term Debt to Equity	-0.79	-0.94	-0.75	-1.00	-1.89	-5.58	5.56	-1.07	-1.27	-3.55
Financial Leverage	1.05	1.34	1.17	0.87	2.07	4.88	-24.95	1.51	57.52	-3.09
Leverage Ratio	-2.43	-3.05	-2.70	-2.10	-3.92	-9.93	45.15	-5.62	-133.27	5.58
Compound Leverage Factor	-3.04	-3.68	-3.20	-2.48	-4.46	-11.98	58.34	-7.07	-156.99	6.71
Debt to Total Capital	-386.06%	-1,543.78%	-293.61%	28,658.27%	211.79%	121.81%	84.75%	1,499.89%	465.84%	139.17%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-386.06%	-1,543.78%	-293.61%	28,658.27%	211.79%	121.81%	84.75%	1,499.89%	465.84%	139.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	486.06%	1,643.78%	393.61%	-28,558.27%	-111.79%	-21.81%	15.25%	-1,399.89%	-365.84%	-39.17%
Debt to EBITDA	-0.73	-0.62	-0.70	-0.73	-0.84	-0.70	-0.66	-0.60	-0.56	-0.60
Net Debt to EBITDA	0.36	0.57	0.42	0.86	1.49	0.81	1.02	0.20	0.36	0.66
Long-Term Debt to EBITDA	-0.73	-0.62	-0.70	-0.73	-0.84	-0.70	-0.66	-0.60	-0.56	-0.60
Debt to NOPAT	-1.04	-0.87	-0.99	-1.03	-1.18	-0.98	-0.93	-0.84	-0.79	-0.84
Net Debt to NOPAT	0.51	0.80	0.59	1.21	2.10	1.13	1.43	0.29	0.50	0.93
Long-Term Debt to NOPAT	-1.04	-0.87	-0.99	-1.03	-1.18	-0.98	-0.93	-0.84	-0.79	-0.84
Altman Z-Score	-3.65	-2.75	-3.98	-2.88	-2.01	-3.10	-2.07	-6.31	-4.97	-3.17
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.20	5.73	6.48	7.83	10.25	9.46	11.96	9.68	6.12	8.65
Quick Ratio	3.92	5.45	6.11	7.50	9.88	8.91	11.55	8.97	5.92	8.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9.03	167	150	152	135	-22	-11	93	81	66
Operating Cash Flow to CapEx	-1,269,120.00%	-144,484.09%	-153,741.30%	-172,550.00%	-9,220.42%	-3,398.72%	-370,000.00%	-18,536.92%	-9,961.41%	-26,131.34%
Free Cash Flow to Firm to Interest Expense	-0.49	9.01	8.47	8.86	10.33	-2.22	-1.15	10.05	8.43	7.15
Operating Cash Flow to Interest Expense	-3.41	-3.44	-3.98	-4.02	-3.36	-3.16	-2.31	-4.30	-4.27	-3.77
Operating Cash Flow Less CapEx to Interest Expense	-3.41	-3.44	-3.98	-4.02	-3.40	-3.25	-2.31	-4.33	-4.32	-3.79
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.14	0.08	0.03	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	2.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	3.61	2.68	1.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	30.51	14.47	6.68	1.60	0.41	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.69	0.67	0.33	0.09	0.01	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	133.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	101.08	135.96	212.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	528.94	545.47	1,096.48	4,064.86	24,695.42	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-294.30	-409.52	-884.42	-4,064.86	-24,695.42	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-351	-347	-337	-323	-318	-131	-133	-122	-135	-129
Invested Capital Turnover	-0.17	-0.11	-0.04	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-33	-216	-205	-201	-183	-2.54	-11	-114	-114	-96
Enterprise Value (EV)	457	916	498	445	276	475	474	267	406	331
Market Capitalization	555	1,077	602	621	523	589	625	300	467	434
Book Value per Share	($3.71)	($3.14)	($4.00)	($2.54)	($1.27)	($0.31)	$0.40	($2.15)	($1.80)	($0.67)
Tangible Book Value per Share	($3.71)	($3.14)	($4.00)	($2.54)	($1.27)	($0.31)	$0.40	($2.15)	($1.80)	($0.67)
Total Capital	-52	-11	-59	0.52	65	81	115	6.44	20	67
Total Debt	201	176	174	149	138	99	98	97	95	94
Total Long-Term Debt	201	176	174	149	138	99	98	97	95	94
Net Debt	-99	-162	-105	-176	-246	-114	-151	-33	-61	-103
Capital Expenditures (CapEx)	0.01	0.04	0.05	0.04	0.48	0.94	0.01	0.21	0.41	0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-29	-21	-28	-26	-11	-13	-4.17	-22	-22
Debt-free Net Working Capital (DFNWC)	274	309	258	297	359	203	236	125	134	175
Net Working Capital (NWC)	274	309	258	297	359	203	236	125	134	175
Net Nonoperating Expense (NNE)	33	36	37	34	31	18	19	17	22	21
Net Nonoperating Obligations (NNO)	-97	-160	-103	-175	-245	-113	-150	-32	-60	-102
Total Depreciation and Amortization (D&A)	0.82	0.78	0.70	0.69	0.75	0.66	0.40	0.64	0.67	0.74
Debt-free, Cash-free Net Working Capital to Revenue	-46.55%	-110.42%	-214.97%	-1,088.70%	-3,754.40%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	496.64%	1,174.47%	2,599.10%	11,443.91%	52,588.12%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	496.64%	1,174.47%	2,599.10%	11,443.91%	52,588.12%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.99)	($1.32)	($1.56)	($1.42)	($1.44)	($0.76)	($0.84)	($0.89)	($1.33)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	63.18M	64.63M	58.56M	58.37M	51.29M	56.78M	48.50M	42.35M	39.12M	0.00
Adjusted Diluted Earnings per Share	($0.99)	($1.32)	($1.56)	($1.42)	($1.44)	($0.76)	($0.84)	($0.89)	($1.33)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	63.18M	64.63M	58.56M	58.37M	51.29M	56.78M	48.50M	42.35M	39.12M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.64M	68.38M	59.59M	58.54M	58.48M	57.25M	56.80M	43.61M	41.97M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-42	-50	-54	-49	-49	-25	-22	-21	-33	-30
Normalized NOPAT Margin	-140.21%	-303.07%	-738.80%	-2,561.08%	-7,171.92%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-250.98%	-523.34%	-1,248.58%	-4,333.26%	-11,667.16%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3.19	-3.83	-4.35	-4.08	-5.36	-3.55	-3.30	-3.26	-4.87	-4.59
NOPAT to Interest Expense	-2.24	-2.68	-3.05	-2.85	-3.75	-2.47	-2.31	-2.28	-3.40	-3.21
EBIT Less CapEx to Interest Expense	-3.19	-3.83	-4.35	-4.08	-5.40	-3.64	-3.30	-3.28	-4.91	-4.60
NOPAT Less CapEx to Interest Expense	-2.24	-2.68	-3.05	-2.85	-3.79	-2.56	-2.31	-2.31	-3.44	-3.22
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Phathom Pharmaceuticals' Financials

When does Phathom Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Phathom Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Phathom Pharmaceuticals' net income changed over the last 2 years?

Phathom Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$334.33 million in 2024, rising from -$197.72 million in 2022. The previous period was -$201.59 million in 2023. See Phathom Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Phathom Pharmaceuticals's operating income?

Phathom Pharmaceuticals's total operating income in 2024 was -$277.47 million, based on the following breakdown:

Total Gross Profit: $47.28 million
Total Operating Expenses: $324.75 million

How has Phathom Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Phathom Pharmaceuticals' total revenue changed from $0.00 in 2022 to $55.25 million in 2024, a change of 5,525,200,000.0%.

How much debt does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals' total liabilities were at $631.90 million at the end of 2024, a 29.9% increase from 2023, and a 163.7% increase since 2022.

How much cash does Phathom Pharmaceuticals have?

In the past 2 years, Phathom Pharmaceuticals' cash and equivalents has ranged from $155.39 million in 2022 to $381.39 million in 2023, and is currently $297.26 million as of their latest financial filing in 2024.

How has Phathom Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Phathom Pharmaceuticals' book value per share changed from -1.80 in 2022 to -3.71 in 2024, a change of 106.3%.

Related Companies

This page (NASDAQ:PHAT) was last updated on 6/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Financials

Frequently Asked Questions About Phathom Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Financials

Annual Income Statements for Phathom Pharmaceuticals

Quarterly Income Statements for Phathom Pharmaceuticals

Annual Cash Flow Statements for Phathom Pharmaceuticals

Quarterly Cash Flow Statements for Phathom Pharmaceuticals

Annual Balance Sheets for Phathom Pharmaceuticals

Quarterly Balance Sheets for Phathom Pharmaceuticals

Annual Metrics And Ratios for Phathom Pharmaceuticals

Quarterly Metrics And Ratios for Phathom Pharmaceuticals

Frequently Asked Questions About Phathom Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools